Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology
+$0.03 today
- Market cap
- $103.50M
- Beta
- 0.42
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.19
Volume 1.28M
Average 0.21M
TLSA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Tiziana Life Sciences LtdNASDAQ: TLSA
Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025
Depreciation & amortization grows 139.3% year over year
Q4 FY2025 depreciation & amortization of $146K rose 139.3% year over year. Over 3 fiscal years it compounded at +55.1% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 234K USD
- Year-over-year change
- +88.7%
- 4-year CAGR
- +5.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 234K | +88.7% |
| FY2024 | 2024-12-31 | 124K | +2.2% |
| FY2023 | 2023-12-31 | 121.34K | +93.6% |
| FY2022 | 2022-12-31 | 62.68K | -67.0% |
| FY2021 | 2021-12-31 | 190.2K | — |
Depreciation & Amortization vs competitors
How TLSA compares with its peers on the latest reported figures
- TLSA's FY2025 depreciation & amortization of $234K is the 6th highest of the 9 companies compared; the peer median is $344.91K.
- Its year-over-year change of +88.7% is the 2nd highest of 9, against a peer median of -20.7%.
- Over three fiscal years its annual growth of +55.1% compares with a peer median of -7.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.09M | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $1.51M | -26.6% | -22.8% | — | |
| LTM Mar 2026 | $628K | -48.8% | -19.7% | — | |
| LTM Mar 2026 | $398.22K | +164.2% | +454.8% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $291.61K | +6.0% | +24.9% | — |
| FY2025 | $234K | +88.7% | +55.1% | — | |
| LTM Mar 2026 | $23.33K | -14.7% | +0.0% | 0.3% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $22K | -88.5% | -20.8% | — |
| FY2025 | $2.56K | -33.7% | +3.2% | — | |
| Peer median (excluding TLSA) | $344.91K | -20.7% | -7.7% | 2.4% | |
Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 234K |
| Gross Profit | 0 | 0 | 0 | 0 | (234K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 17.82M | 15.92M | 10.25M | 5.23M | 10.28M |
| Selling, General & Admin | 1.15M | 4.76M | 8.26M | 10.28M | 10.77M |
| Operating Expenses | 36.93M | 17.93M | 22.73M | 15.79M | 21.05M |
| Depreciation & Amortization | 190.2K | 62.68K | 121.34K | 124K | 234K |
| EBITDA | (35.53M) | (18.85M) | (21.66M) | (16.62M) | (21.05M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.93M) | (17.93M) | (22.73M) | (15.79M) | (21.28M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.46M | 814K | 19K |
| Interest Expense | 237.41K | 8.6K | 12.64K | 6K | 18K |
| Other Income / Expenses | 967.18K | (996.78K) | 937.89K | (952K) | 2.85M |
| Income Before Tax | (35.96M) | (18.92M) | (21.79M) | (16.75M) | (18.43M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (4.37M) | 0 | 567.54K | (4.88M) | 0 |
| Net Income | (31.59M) | (18.92M) | (22.36M) | (11.86M) | (18.43M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.64) | (0.36) | (0.42) | (0.22) | (0.32) |
| EPS (Diluted) | (0.64) | (0.36) | (0.42) | (0.22) | (0.32) |
| Weighted Avg Shares | 48.97M | 50.76M | 50.76M | 53.34M | 59.14M |
| Weighted Avg Shares (Diluted) | 48.97M | 50.76M | 50.76M | 53.34M | 59.14M |
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.